Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

MET mutations leading to exon 14 skipping (METΔex14) are strong molecular drivers for non–small‐cell lung cancer (NSCLC). Capmatinib is a highly potent, selective oral MET inhibitor that showed clinically meaningful efficacy and a manageable safety profile in a global phase II study (GEOMETRY mono‐1...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Seto, Takashi, Ohashi, Kadoaki, Sugawara, Shunichi, Nishio, Makoto, Takeda, Masayuki, Aoe, Keisuke, Moizumi, Sanae, Nomura, Satoshi, Tajima, Takeshi, Hida, Toyoaki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2021
Aiheet:
ORIGINAL ARTICLES
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8019204/
https://ncbi.nlm.nih.gov/pubmed/33506571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14826
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia